Protagonist Therapeutics, Inc - Common Stock (PTGX)
CUSIP: 74366E102
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 62,457,444
- Total 13F shares
- 70,977,321
- Share change
- +5,992,814
- Total reported value
- $3,923,985,934
- Put/Call ratio
- 110%
- Price per share
- $55.27
- Number of holders
- 273
- Value change
- +$344,775,786
- Number of buys
- 169
- Number of sells
- 123
Quarterly Holders Quick Answers
What is CUSIP 74366E102?
CUSIP 74366E102 identifies PTGX - Protagonist Therapeutics, Inc - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74366E102:
Top shareholders of PTGX - Protagonist Therapeutics, Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
16%
|
9,736,767
|
$470,870,063 | — | 31 Mar 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
9.8%
|
6,107,006
|
$295,334,810 | — | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
9.2%
|
5,719,415
|
$276,590,909 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.8%
|
4,277,218
|
$206,846,263 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13D/G
13F
|
STATE STREET CORPORATION · Company |
5.2%
|
3,207,774
|
$170,012,022 | +$26,561,215 | 30 Jun 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
4.8%
|
3,000,000
|
$145,080,000 | — | 31 Mar 2025 | |
| BVF INC/IL |
13F
|
Company |
4.1%
|
2,575,015
|
$124,527,725 | — | 31 Mar 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.9%
|
2,449,183
|
$118,442,490 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
1,423,559
|
$68,858,724 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.1%
|
1,322,006
|
$63,934,000 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.7%
|
1,091,271
|
$52,773,866 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.6%
|
987,370
|
$47,749,214 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.5%
|
939,669
|
$45,442,393 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
897,699
|
$43,412,724 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.4%
|
859,648
|
$41,572,577 | — | 31 Mar 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
1.2%
|
733,014
|
$35,448,557 | — | 31 Mar 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
1.1%
|
685,824
|
$33,166,449 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1%
|
639,507
|
$30,926,559 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
1%
|
631,893
|
$30,558,345 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.89%
|
557,718
|
$26,971,242 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.89%
|
555,551
|
$26,866,446 | — | 31 Mar 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.88%
|
547,116
|
$26,458,530 | — | 31 Mar 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.8%
|
500,000
|
$24,180,000 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.8%
|
497,105
|
$24,040,047 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.77%
|
478,343
|
$23,132,668 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.76%
|
471,745
|
$22,813,587 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.75%
|
468,899
|
$22,675,955 | — | 31 Mar 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
0.71%
|
445,440
|
$21,541,478 | — | 31 Mar 2025 | |
| Focus Partners Wealth |
13F
|
Company |
0.7%
|
435,097
|
$21,041,291 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.64%
|
400,000
|
$19,344,000 | — | 31 Mar 2025 | |
| MANGROVE PARTNERS IM, LLC |
13F
|
Company |
0.63%
|
395,383
|
$19,120,722 | — | 31 Mar 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.61%
|
379,649
|
$18,359,000 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.6%
|
376,863
|
$18,225,093 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.56%
|
352,871
|
$17,064,841 | — | 31 Mar 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.56%
|
347,095
|
$16,785,513 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.55%
|
343,504
|
$16,611,853 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.55%
|
343,411
|
$16,607,356 | — | 31 Mar 2025 | |
| Artia Global Partners LP |
13F
|
Company |
0.53%
|
333,851
|
$16,145,034 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.52%
|
323,567
|
$15,647,700 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.48%
|
298,827
|
$14,451,273 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.47%
|
295,593
|
$14,294,877 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.46%
|
287,301
|
$13,893,876 | — | 31 Mar 2025 | |
| Skandinaviska Enskilda Banken AB (publ) |
13F
|
Company |
0.4%
|
248,950
|
$12,039,222 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.38%
|
235,073
|
$11,368,130 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.33%
|
208,756
|
$10,095,441 | — | 31 Mar 2025 | |
| BURNEY CO/ |
13F
|
Company |
0.32%
|
201,985
|
$9,767,994 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.31%
|
193,300
|
$9,347,988 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.31%
|
192,239
|
$9,296,678 | — | 31 Mar 2025 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.3%
|
189,031
|
$9,141,539 | — | 31 Mar 2025 | |
| Checkpoint Capital L.P. |
13F
|
Company |
0.28%
|
175,184
|
$8,471,898 | — | 31 Mar 2025 |
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q2 2025
As of 30 Jun 2025,
Protagonist Therapeutics, Inc - Common Stock (PTGX) was held by
273 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
70,977,321 shares.
The largest 10 holders included
BlackRock, Inc., FARALLON CAPITAL MANAGEMENT LLC, RTW INVESTMENTS, LP, VANGUARD GROUP INC, Deep Track Capital, LP, BVF INC/IL, STATE STREET CORP, UBS Group AG, JOHNSON & JOHNSON, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
272
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
273
Q2 2025 holders
273
Holder diff
0
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.